Zomedica (ZOM) Twitter Mentions Statistics 2025

17 60.5%

1W 63% 1M 71.2% 3M 94.6%

Est. daily mentions on Twitter.

Similar companies

Company		Twitter Mentions
	Johnson & Johnson JNJ	143 66.4%
	Eli Lilly and Company LLY	400 43.7%
	Pfizer PFE	433 34.9%
	Astrazeneca AZN	131 98.5%
	AbbVie ABBV	218 67.8%

Month over Month

Est. daily mentions on Twitter.

Jun 2025	87	25.7%
May 2025	117	49.7%
Apr 2025	233	159.3%
Mar 2025	90	27.2%
Feb 2025	123

How often is Zomedica mentioned on Twitter?

Zomedica was mentioned an estimated 17 times in various tweets yesterday. In the last 30 days, Zomedica has been mentioned around 70 times per day.

Analyzing Twitter Mentions, how is Zomedica performing compared to its industry peers?

Zomedica underperforms its industry peers when it comes to Twitter Mentions, ranking in the 4th percentile.

Why is it important to track Twitter mentions for Zomedica?

By monitoring Twitter mentions for Zomedica, investors gain real-time insights into public sentiment towards the company, its products, and its industry. Positive mentions may indicate growing interest, customer satisfaction, or emerging trends, while negative mentions can alert investors to potential issues, controversies, or market challenges. By tracking these mentions over time, investors can identify patterns, spot emerging trends, and make informed decisions based on the evolving sentiment and public perception of Zomedica, ultimately improving their investment strategies.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.